225 related articles for article (PubMed ID: 23444259)
1. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
Naeini KM; Pope WB; Cloughesy TF; Harris RJ; Lai A; Eskin A; Chowdhury R; Phillips HS; Nghiemphu PL; Behbahanian Y; Ellingson BM
Neuro Oncol; 2013 May; 15(5):626-34. PubMed ID: 23444259
[TBL] [Abstract][Full Text] [Related]
2. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
3. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.
Yang D; Rao G; Martinez J; Veeraraghavan A; Rao A
Med Phys; 2015 Nov; 42(11):6725-35. PubMed ID: 26520762
[TBL] [Abstract][Full Text] [Related]
5. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
[TBL] [Abstract][Full Text] [Related]
6. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
[TBL] [Abstract][Full Text] [Related]
7. Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.
Zhang Z; Jiang H; Chen X; Bai J; Cui Y; Ren X; Chen X; Wang J; Zeng W; Lin S
J Neurooncol; 2014 Aug; 119(1):207-14. PubMed ID: 24828264
[TBL] [Abstract][Full Text] [Related]
8. Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
Henker C; Kriesen T; Fürst K; Goody D; Glass Ä; Pützer BM; Piek J
J Neurooncol; 2016 Feb; 126(3):585-92. PubMed ID: 26603163
[TBL] [Abstract][Full Text] [Related]
9. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
[TBL] [Abstract][Full Text] [Related]
10. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma.
Harris RJ; Cloughesy TF; Pope WB; Godinez S; Natsuaki Y; Nghiemphu PL; Meyer H; Paul D; Behbahanian Y; Lai A; Ellingson BM
J Neurooncol; 2013 Apr; 112(2):257-66. PubMed ID: 23344788
[TBL] [Abstract][Full Text] [Related]
11. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
Wang P; Shi YH; Li JY; Zhang CZ
World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
[TBL] [Abstract][Full Text] [Related]
12. Radiomic analysis of multi-contrast brain MRI for the prediction of survival in patients with glioblastoma multiforme.
Chaddad A; Desrosiers C; Toews M
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():4035-4038. PubMed ID: 28325002
[TBL] [Abstract][Full Text] [Related]
13. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
14. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
Stringfield O; Arrington JA; Johnston SK; Rognin NG; Peeri NC; Balagurunathan Y; Jackson PR; Clark-Swanson KR; Swanson KR; Egan KM; Gatenby RA; Raghunand N
Tomography; 2019 Mar; 5(1):135-144. PubMed ID: 30854451
[TBL] [Abstract][Full Text] [Related]
15. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Mischel PS; Pope WB
Neuro Oncol; 2011 Apr; 13(4):401-9. PubMed ID: 21324937
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
17. Volumetric assessment of glioblastoma and its predictive value for survival.
Henker C; Hiepel MC; Kriesen T; Scherer M; Glass Ä; Herold-Mende C; Bendszus M; Langner S; Weber MA; Schneider B; Unterberg A; Piek J
Acta Neurochir (Wien); 2019 Aug; 161(8):1723-1732. PubMed ID: 31254065
[TBL] [Abstract][Full Text] [Related]
18. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
[TBL] [Abstract][Full Text] [Related]
20. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
